



# Immatics

## Developing Cancer Immunotherapies for Patients with an Unmet Need

---

Dr. Harpreet Singh, Co-Founder & CEO

Fort Bend Economic Development Council

April 20, 2022




*Delivering the Power of T cells to Cancer Patients*


© Immatics. Not for further reproduction or distribution.

## Immatics US History

- Immatics US was created in 2015 as a joint venture between its parent company (Immatics GmbH) and MD Anderson Cancer Center with support of a \$20M CPRIT grant awarded by the State of Texas
- Immatics is a clinical-stage company with a significant R&D infrastructure in the US. Its first clinical site was at MD Anderson Cancer Center and that has been expanded to include other US sites and several others in Germany
- Immatics N.V. (NASDAQ: IMTX) is the largest public traded biotech company in the region
- Today, Immatics US has over 150 employees in the Texas Medical Center. A large portion are highly qualified scientists.



# Our Pipeline of TCR-based Adoptive Cell Therapies and Bispecifics




<sup>1</sup> Phase 1a: Dose escalation, Phase 1b: Dose expansion; <sup>2</sup> Opdivo® (nivolumab): programmed death-1 (PD-1) immune checkpoint inhibitor;

\* Immatics proprietary ACTallo® platform utilizing Editas' CRISPR gene editing technology

# Immatics' Partnerships with Pharma Partners


## Synergistic Expertise that Can Foster Transformative Innovations for ACT and Bispecifics




# Leveraging the Immune System against Cancer – How Does it Work?

Cells in the body process and present antigens through the peptide-HLA complex

T cells can detect antigens on infected and cancer cells through their T cell receptor



# Leveraging the Immune System against Cancer – How Does it Work?





# ACTengine® IMA203 – Case Study Patient IMA203-DL3-01

## Confirmed Partial Response with Deepening Tumor Regression in Multiple Lesions

62-year-old female patient

Metastatic uveal melanoma with high tumor burden in multiple organs


Infused at refractory disease after failing 4 prior lines of therapy incl. 2 lines of checkpoint inhibitors

Received **total dose of 0.59 bn** (0.36 bn/m<sup>2</sup>) transduced cells directed against PRAME target peptide/HLA

### Tumor Response

**Best response (RECIST1.1):  
PR (confirmed)**

**Target Lesions decreased at week 6 post treatment to -40%, response deepened at week 12 to -68%**




# ACTengine® IMA203 – Best Overall Response

## IMA203 Continues to Deliver Objective Responses in Major Solid Tumor Types


### Phase 1a (Dose Escalation)

N=27<sup>#</sup>



### Phase 1b (Cohort A)

N=5




Confirmed objective responses across a broad spectrum of different tumor types such as cutaneous melanoma, uveal melanoma, head and neck cancer, ovarian cancer, synovial sarcoma

Data cut-off – 06-Sept-2022

\* Maximum change of target lesions and RECIST 1.1 BOR at different timepoints; <sup>#</sup> Synovial sarcoma patient (DL3) PD at week 6 not shown as target lesions were not evaluable; PD: Progressive disease; SD: Stable disease; PR: Partial response; cPR: Confirmed partial response; BL: Baseline



# ACTengine® IMA203 Targeting PRAME Immatics' Personalized TCR-T Approach




## Immatics Weatherford Facility, Stafford, TX



**13223 Murphy Rd, Stafford, TX 77477**

# Weatherford Farms, Stafford, TX

## 100,000 sqft



- Specifications**
- Seating built to accommodate up to 300 employees (offices & cubicles)
  - R&D and Quality control laboratories
  - State of the art GMP manufacturing facility designed for cell therapy manufacturing
    - Starting with 4 manufacturing suites with matching quality control and warehouse areas
    - Highly modular and expandable
    - Independent air handling per suite
    - Max. capacity of approx. 1000 patients/yr (6 patient per week per suite) at the current manufacturing duration of 7 days

OVERALL FLOOR PLAN  
SCALE: 1/32" = 1'-0"

## Immatics' Impact on Fort Bend County

- Part of the facility includes a first-class GMP manufacturing site that will be used for making FDA-approved commercial cancer drugs
- This construction represents an investment of more than \$25m in 2023 alone
- The move will be gradual, starting in summer 2023 and will move over 200 highly qualified jobs within the next year to Stafford, TX
- Immatics' workforce has been growing at a rate of 25-35% per year. We expect to continue to sustain a major growth in the coming years
- Immatics will continue its partnership with MD Anderson. It is committed to being an active player in the Fort Bend ecosystem and will look to recruit most of its workforce locally
- Immatics is eager to develop its relationships with key players in Fort Bend and welcomes meeting each of you!

## Your Points of Contact at Immatics US, Inc.



**Emmanuelle Schuler**  
Site Head & VP, Administration  
and Operations




**Steffen Walter**  
Chief Operating Officer  
Co-Founder Immatics US



**Harpreet Singh**  
Chief Executive Officer  
Co-Founder Immatics





DELIVERING THE POWER  
OF **T CELLS** TO  
CANCER PATIENTS

Thank you

[www.immatics.com](http://www.immatics.com)

